Parthenon LLC Has $3.36 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Parthenon LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 1.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,765 shares of the company’s stock after acquiring an additional 98 shares during the quarter. Parthenon LLC’s holdings in Eli Lilly and Company were worth $3,361,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $27,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $36,000. Finally, Family CFO Inc bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 6.0 %

Shares of LLY stock traded up $44.36 on Tuesday, hitting $781.56. The stock had a trading volume of 7,432,651 shares, compared to its average volume of 3,071,009. The business has a 50 day moving average of $761.41 and a 200 day moving average of $669.21. The stock has a market cap of $742.61 billion, a price-to-earnings ratio of 134.75, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 12-month low of $392.26 and a 12-month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.09 earnings per share. As a group, analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Wall Street Analyst Weigh In

LLY has been the topic of a number of analyst reports. Bank of America upped their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $731.55.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.